We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Palatin (PTN) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Palatin (PTN - Free Report) closed at $1 in the latest trading session, marking a +0.37% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.62%. Meanwhile, the Dow lost 0.25%, and the Nasdaq, a tech-heavy index, lost 0.74%.
Heading into today, shares of the biopharmaceutical company had lost 22.3% over the past month, lagging the Medical sector's loss of 1.47% and the S&P 500's gain of 2.8% in that time.
Investors will be hoping for strength from PTN as it approaches its next earnings release. The company is expected to report EPS of -$0.02, down 133.33% from the prior-year quarter.
Any recent changes to analyst estimates for PTN should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 63.64% higher. PTN is currently sporting a Zacks Rank of #2 (Buy).
Digging into valuation, PTN currently has a Forward P/E ratio of 3.68. Its industry sports an average Forward P/E of 23.55, so we one might conclude that PTN is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 58, putting it in the top 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Palatin (PTN) Gains As Market Dips: What You Should Know
Palatin (PTN - Free Report) closed at $1 in the latest trading session, marking a +0.37% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.62%. Meanwhile, the Dow lost 0.25%, and the Nasdaq, a tech-heavy index, lost 0.74%.
Heading into today, shares of the biopharmaceutical company had lost 22.3% over the past month, lagging the Medical sector's loss of 1.47% and the S&P 500's gain of 2.8% in that time.
Investors will be hoping for strength from PTN as it approaches its next earnings release. The company is expected to report EPS of -$0.02, down 133.33% from the prior-year quarter.
Any recent changes to analyst estimates for PTN should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 63.64% higher. PTN is currently sporting a Zacks Rank of #2 (Buy).
Digging into valuation, PTN currently has a Forward P/E ratio of 3.68. Its industry sports an average Forward P/E of 23.55, so we one might conclude that PTN is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 58, putting it in the top 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.